Diabetic Macular Edema
Conditions
Brief summary
It will investigate a novel treatment approach for diabetic macular edema (DME), which causes vision impairment in diabetic patients. It will focuse on the efficacy and safety of administering triamcinolone acetonide via suprachoroidal injection, targeting the space between the sclera and choroid.
Detailed description
This method aims to enhance drug delivery to the retina, potentially improving outcomes compared to conventional treatments. Participants receive suprachoroidal injections, and the study measures changes in macular thickness and visual acuity. The study's findings could offer a promising alternative to existing DME treatments, aiming to provide better management of the condition and improved patient quality of life.
Interventions
BEHAVIORALDiabetic Macular Edema
observing the eye behavior in Diabetic Macular Edema
Sponsors
Superior University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Above 30 years old patients male and female * Diabetic patient * Diabetic patient for more than 2 years * Macular thickness of more than 280um
Exclusion criteria
* Patient below 30 years * Patients having media opacity * Patients with other systemic problems * Uncooperative patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Acuity Testing | 12 Months | Visual acuity testing evaluates the participants' ability to discern letters or symbols at a standardized distance, providing a measure of vision clarity. This tool helps determine the functional improvement in vision. |
| Optical Coherence Tomography | 12 months | OCT is employed to assess changes in macular thickness, providing detailed cross-sectional images of the retina. This non-invasive imaging technique helps quantify the extent of macular edema and monitoring |
Countries
Pakistan
Outcome results
None listed